Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] AHL operates on a third party contract manufacturing of dermatological products on a need based formula. It posted higher margins from FY24 onwards following cost-control and tailor made high-margin products. It has emerged as an establish player in the field with user friendly quality products. Based on its recent financial performance, the issue appears fully priced. The company is operating with its asset light model in an emerging segment. Well-informed investors may park funds for the medium to long term. Read detail review...
Amwill Healthcare Limited peer comparison with similar listed entities. (As on March 28, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Amwill Healthcare Limited | 8.04 | 8.04 | 11 | 73.06 | 10.09 | ||
| Vaishali Pharma Limited | 0.68 | 0.64 | 39.97 | 26.45 | 1.68 | Standalone | |
| Trident Lifeline Ltd | 6.13 | 6.13 | 45.81 | 45.06 | 13.37 | 14 | Standalone |
Source: All the financial information for listed industry peers mentioned above is available on a standalone basis, sourced from the financial reports of the peer company uploaded on the NSE/BSE website for the year that ended March 31, 2024.
Notes:
Amwill Health Care IPO Reviews, analysis and views by popular members. Read Amwill Health Care Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP